Abstract 320P
Background
Ovarian cancer is 3rd most common malignancy in Indian women and 8th common cause of cancer related death in India. The aim for this study was to evaluate clinicopathological factors, patterns of treatment, progression free survival (PFS) and overall survival (OS) in Indian patients with advanced ovarian cancer.
Methods
This is a retrospective analysis of patients with stage III-IV ovarian cancer treated at HCG Cancer Center, Ahmedabad from June 2018- March 2023. Patients were identified using the institutional tumor registry and medical records and data was collected.
Results
Out of total 94 patients identified; 79 patients were eligible for further analysis. Median age was 55 years (range 29 to 76 years). 62 (78%) patients had stage III (IIIA-5,IIIB-3, IIIc-44) & 17 (22%) had stage IV (IVA-10, IVB-7). Most common histology was high grade serous carcinoma in 76 (96%) patients. Majority of patients received neoadjuvant chemotherapy followed by interim cytoreductive surgery (CRS), [61 patients (78%)] whereas 18 patients (22 %) underwent upfront surgery. Median duration of neoadjuvant chemotherapy was 3 months. 21 (26.57%) patients were treated with hyperthermic intraperitoneal chemotherapy (HIPEC). 60 patients (76%) received maintenance therapy [43 patients bevacizumab, 10 patients PARP (poly ADP ribose polymerase) inhibitor and 6 patients received both]. 33 patients (41%) developed recurrence among which 32 received further chemotherapy. In recurrent setting, patients received a median 3 lines of systemic therapy (range 0-5). Genetic testing was offered to all patients at the time of diagnosis, but only 36 (45%) patients opted for it. BRCA1 mutation was detected in 8 patients (22.2%), BRCA2 mutation in 4 (11%). Median follow up was 17 months. Median PFS was 20 months with 95% CI (16-22) & Median OS was not reached, 5-year OS was 32.1%.
Conclusions
Median PFS and OS in advanced ovarian cancer at our institute is comparable to global standards. With the availability of biosimilars and genetic testing, more patients are able to access maintenance therapies. Hopefully more patients can access standard of care therapies which will help close the gap between less developed and developed countries in terms of long term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract